The prostate cancer drug market is heading toward boom times, according to new predictions by two leading business publications.
Barron’s and the Wall Street Journal are both reporting the market for new drugs that treat advanced cases of prostate cancer -- a leading cause of death in men -- is projected to surge by the end of the decade. Barron's predicts the market could rise from approximately $1 billion to $8 billion in that time.
“We count at least 10 late-stage trial results due for release within the next four years and believe that the potential success of any one particular therapeutic cannot be analyzed in isolation,” Barron’s reported, in an analysis of new drugs headed to market.
Among the next-generation products: Medivation's MDV3100; Algeta's Alpharadin; Exelixis' cabozantinib; Dendreon's Provenge; Johnson & Johnson's Zytiga; and Amgen's Xgeva.
If true, the market surge would contrast with years of frustrating results on new prostate cancer treatments, according to the Journal. The pharmaceutical industry has turned out just five new treatments for advanced prostate cancer in three years.